Login / Signup

Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.

Alessandro LazzaroDiana BianchiniElio Gentilini CacciolaIvano MezzaromaMario FalcianoCarolina AndreoniCaterina FimianiLetizia SantinelliLuca MaddaloniGinevra BuganiGiancarlo CeccarelliClaudio Maria MastroianniGabriella d'Ettorre
Published in: Viruses (2023)
BIC/FTC/TAF is an effective, safe, and well-tolerated switching strategy for PLWH, especially among those older than 55.
Keyphrases
  • hiv infected
  • antiretroviral therapy
  • middle aged
  • randomized controlled trial
  • placebo controlled
  • study protocol